You are currently viewing a new version of our website. To view the old version click .
Scientia Pharmaceutica
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Article
  • Open Access

21 May 2008

Rosiglitazone modifies PEDF gene expression and protein levels in the Koletsky rat choroid-RPE complex

,
and
1
Department of Physiology, Southern Illinois University School of Medicine
2
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN 38163
3
Department of Animal Science, Food and Nutrition, Southern Illinois University, Carbondale, IL 62901
*
Author to whom correspondence should be addressed.

Abstract

The purpose of this study was to determine whether rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)γ ligand, altered growth factor expression in the choroid-RPE complex of Koletsky rats. Using lean and obese Koletsky rats fed a normal or rosiglitazone-supplemented diet, gene and protein expression of vascular endothelial growth factor (VEGF), pigment epithelial derived growth factor (PEDF), angiopoietin 1, and its receptor, Tie-2, were assessed. Both gene expression and protein expression of PEDF were significantly increased in both obese and lean Koletsky rats treated with rosiglitazone diet. Gene expression of VEGF, angiopoietin-1 and Tie-2 were increased after rosiglitazone treatment, without changes in protein expression. Since PPARγ ligands have been implicated in vascular remodeling, these results suggest that upregulation of PEDF expression may be a potential mechanism in the rat choroid-RPE complex.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.